Table 1

 Lipid content in exosomes and enrichment from the originating cells.

Lipids	PC-3 cells [34]		PC-3 cells + HG [43]		Oli-neu cells [35]		B-lymphocytes [36]		Mast cells [37]		Dendritic cells [37]		Reticulocytes [38]		Prosta. <sup>a</sup> 100 nm [39]	Prosta. <sup>a</sup> 50 nm [39]	Urine [40]	Nematodes
	%	Factor	%	Factor	% <sup>b</sup>	Factor	%	Factor	% <sup>c</sup>	Factor	%c,d	Factor	%	Factor	%	%	%	%e
CHOL	43.5	2.3	59	1.7	43	2.3	42.1	3.0	15	1.0	?	?	47	1.03	54.8	54.1	63	7
SM	16.3	2.4	9.1	2.0	8.2	1.5	23.0	2.3 <sup>f</sup>	12	2.8	20	2.2	8.4 <sup>f</sup>	1.31	28.6	14.3	11.7	3
PC	15.3	0.31	10.8	0.33	26.7	0.67	$(20.3)^{g}$	$(0.76)^{g}$	28	0.66	26	0.6	23.5	1.03	2.3	1.3	2.7	4
PS	11.7	2.1	6.9	1.2	14.9	3.0	$(20.3)^{g}$	$(0.76)^{8}$	$(16)^{g}$	$(1.2)^{g}$	$(19)^{g}$	$(1.6)^{g}$	5.9	0.92	7.1	5.4	13.2	15
PE	5.8	0.55	1.1	0.21	10.9	1.0	$(14.6)^{g}$	$(0.7)^{g}$	24	1.08	26	1.13	12.7	0.84	0.6	0.3	<loq< td=""><td>13</td></loq<>	13
PE O/P	3.3	1.2	4.7	0.81			$(14.6)^{g}$	$(0.7)^{g}$									4.6	47
DAG	1.5	1.5	1.1	0.92													0.1	
PC O/P	0.81	0.40	0.7	0.28														8
HexCer	0.76	3.8	2.3	2.1	?	2.0									5.6	23.3	1.9	
Cer	0.32	1.3	0.7	1.2	?	3.3											0.1	
PG	0.17	0.17	0.1	0.07														
PA	0.16	1.8	0.1	0.33			$(20.3)^{g}$	$(0.76)^{g}$										
PI	0.13	0.13	0.3	0.16			$(20.3)^{g}$	$(0.76)^{g}$	$(16)^{g}$	$(1.2)^{g}$	$(19)^{g}$	$(1.6)^{g}$	2.4	1.1	1.1	1.3		
LacCer	0.12	3.0	0.7	1.8													0.8	
LysoPI	0.09	2.3	_	_														
LysoPE	0.09	1.3	-	-														
CE	0.08	0.38	_	_													0.3	
Gb3	0.02	2.0 <sup>h</sup>	-	-													1.1	
Out/In	1.47		1.49		1.35		?		1.15		1.22		1.52		4.1	5.6	1.03	0.20
Lipid analysis	MS		MS		MS		TLC		TLC/ GLC		TLC/ GLC		TLC		LC-MS	LC-MS	MS	MS
Exosome prep. <sup>i</sup>	SFM + SUC SFM + SUC		SUC	SFM + SC	+ SUC	uFCS + SUC + SG + immunocapture		uFCS -	+ SUC	uFCS + SUC		uFCS	+ SUC	SUC + SEC + SG	SUC + SEC + SG	SUC	SFM + SUC	

<sup>%:</sup> Percent of total lipid quantified.

Factor: Factor of enrichment from cells to exosomes

Out/In: Sum of sphingolipids and lipids with the phosphocholine head group divided by all other lipids reported (except CHOL).

LOQ: Limit of quantification.

- [34] Llorente A, Skotland T, Sylvanne T, Kauhanen D, Rog T, Orlowski A, et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim Biophys Acta 2013;1831:1302–9.
- [35] Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008;319:1244–7.
- [36] Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Mobius W, Hoernschemeyer J, et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 2003;278:10963–72.
- [37] Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux JF, et al. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J 2004;380:161–71.
- [38] Vidal M, Sainte-Marie J, Philippot JR, Bienvenue A. Asymmetric distribution of phospholipids in the membrane of vesicles released during in vitro maturation of guinea pig reticulocytes: evidence precluding a role for "aminophospholipid translocase". J Cell Physiol 1989;140:455–62.
- [39] Brouwers JF, Aalberts M, Jansen JW, Van NG, Wauben MH, Stout TA, et al. Distinct lipid compositions of two types of human prostasomes. Proteomics 2013;13: 1660–6.
- [40] Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, et al. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur J Cancer 2017;70:122–32.
- [41] Simbari F, McCaskill J, Coakley G, Millar M, Maizels RM, Fabrias G, et al. Plasmalogen enrichment in exosomes secreted by a nematode parasite versus those derived from its mouse host: implications for exosome stability and biology. J Extracell Vesicles 2016;5:30741.

a Prosta = Prostasomes.

b These data are recalculated by assuming same level of CHOL as in [34]; the absolute amounts of CHOL, Cer and HexCer were not reported.

c Recalculated from their data.

d CHOL not reported; the sum for the other lipid classes is 100% (including LysoPC not included in this table).

<sup>&</sup>lt;sup>e</sup> Recalculated from their data; lyso ethers and lyso acyl lipids are not shown.

<sup>&</sup>lt;sup>f</sup> Sum of SM and the ganglioside GM3.

<sup>&</sup>lt;sup>g</sup> Sum for all classes shown in parentheses and having the same numbers.

h Enrichments of other GSLs (GM1, GM2, GM3 and GD1) are shown in Fig. 1; due to lack of standards these GSLs could not be quantified as the other lipid classes.

i Exosome prep.: Methods used to isolate the exosome preparations. SFM: serum free medium; SUC: sequential centrifugation; SG: sucrose gradient; uFCS: ultracentrifuged fetal calf serum; SEC: size exclusion chromatography.

[43] Phuyal S, Skotland T, Hessvik NP, Simolin H, Overbye A, Brech A, et al. The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells. J Biol Chem 2015;290:4225–37.